Reported Consolidated quarterly numbers for Piramal Pharma are:
Net Sales at Rs 1,933.71 crore in June 2025 down 0.89% from Rs. 1,951.14 crore in June 2024.
Story continues below Advertisement
Quarterly Net Loss at Rs. 81.70 crore in June 2025 up 7.83% from Rs. 88.64 crore in June 2024.
EBITDA stands at Rs. 165.10 crore in June 2025 down 26.3% from Rs. 224.03 crore in June 2024.
Piramal Pharma shares closed at 204.35 on July 25, 2025 (NSE)
Story continues below Advertisement
| Piramal Pharma | | Consolidated Quarterly Results | in Rs. Cr. |
|
| Jun'25 | Mar'25 | Jun'24 | | Net Sales/Income from operations | 1,933.71 | 2,754.07 | 1,951.14 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 1,933.71 | 2,754.07 | 1,951.14 | | EXPENDITURE | | Consumption of Raw Materials | 524.35 | 203.68 | 471.48 | | Purchase of Traded Goods | 342.83 | 546.72 | 314.77 | | Increase/Decrease in Stocks | -173.13 | 204.58 | -111.88 | | Power & Fuel | -- | -- | -- | | Employees Cost | 618.59 | 612.01 | 579.69 | | Depreciation | 197.28 | 242.76 | 184.55 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 514.37 | 626.09 | 492.59 | | P/L Before Other Inc., Int., Excpt. Items & Tax | -90.58 | 318.23 | 19.94 | | Other Income | 58.40 | 42.03 | 19.54 | | P/L Before Int., Excpt. Items & Tax | -32.18 | 360.26 | 39.48 | | Interest | 86.15 | 103.68 | 106.96 | | P/L Before Exceptional Items & Tax | -118.33 | 256.58 | -67.48 | | Exceptional Items | 20.74 | -- | -- | | P/L Before Tax | -97.59 | 256.58 | -67.48 | | Tax | 2.68 | 119.30 | 43.56 | | P/L After Tax from Ordinary Activities | -100.27 | 137.28 | -111.04 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -100.27 | 137.28 | -111.04 | | Minority Interest | -- | -- | -- | | Share Of P/L Of Associates | 18.57 | 16.22 | 22.40 | | Net P/L After M.I & Associates | -81.70 | 153.50 | -88.64 | | Equity Share Capital | 1,324.82 | 1,324.34 | 1,322.95 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -0.62 | 1.16 | -0.67 | | Diluted EPS | -0.62 | 1.16 | -0.67 | | EPS After Extra Ordinary | | Basic EPS | -0.62 | 1.16 | -0.67 | | Diluted EPS | -0.62 | 1.16 | -0.67 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
